1 Global Nicotinamide Riboside (NR) Market Outlook
The global Nicotinamide Riboside (NR) market is projected to exhibit substantial growth in the coming years, with a CAGR of 34.15% from 2024 to 2033, reaching a total market size of $201737 K USD in 2024. Nicotinamide Riboside (NR) is a pyridine-nucleoside similar to vitamin B3, which plays a crucial role in cellular processes by supporting the production of nicotinamide adenine dinucleotide (NAD+). NAD+ is a vital coenzyme involved in various metabolic reactions, including energy production and DNA repair. NR acts as a precursor to NAD+ and its reduced forms (NADH, NADP+, and NADPH), making it an essential component in cellular health and longevity. As a dietary supplement, NR has gained significant attention for its potential anti-aging properties and ability to enhance overall cellular function. This has led to its increasing use in the nutraceutical and cosmetic industries, where it is incorporated into products aimed at improving skin health and combating age-related decline.
Figure Global Nicotinamide Riboside (NR) Market Size and Growth Rate (2024-2033)
2 Nicotinamide Riboside (NR) Market Growth Drivers and Constraints
The growth of the global Nicotinamide Riboside (NR) market is influenced by several key drivers and limiting factors. On the positive side, the increasing aging population has created a strong demand for anti-aging products and medical care solutions. NR’s ability to enhance cellular health and potentially delay aging processes makes it an attractive ingredient for health and beauty products. Additionally, continuous research and innovation have uncovered new applications for NR, such as its potential use in treating metabolic and neurodegenerative disorders. This has expanded its market reach beyond traditional supplements into pharmaceuticals and cosmetics.
However, the market also faces several challenges. The COVID-19 pandemic has disrupted supply chains and reduced demand for industrial products, affecting NR manufacturers who rely on a global supply network. Production safety risks, including potential exposure to hazardous materials, also pose a threat to manufacturers. Moreover, the threat of substitutes like Nicotinamide Mononucleotide (NMN) and regulatory hurdles, such as patent restrictions, limit the market’s expansion potential. Environmental regulations and fluctuations in raw material prices further add to the challenges faced by NR producers.
3 Nicotinamide Riboside (NR) Market Innovations and M&A Activities
The Nicotinamide Riboside (NR) market has seen significant technological innovation and corporate activity in recent years. Advances in biotechnology and chemical synthesis have improved the efficiency and scalability of NR production, reducing costs and increasing yields. Companies like ChromaDex have developed patented forms of NR, such as TRU NIAGEN®, which are backed by extensive clinical research and have become popular consumer products. This has led to increased market competition and the need for continuous innovation to maintain a competitive edge.
Corporate mergers and acquisitions have also played a role in shaping the NR market. Major players are constantly seeking to expand their product portfolios and market reach through strategic partnerships and acquisitions. For example, ChromaDex’s collaboration with Nestlé Health Science has led to the development of new NR-based products, such as Celltrient™ Cellular Energy, which combines NR with other health-boosting ingredients. Additionally, companies are investing in research to explore new applications for NR, such as its potential use in treating various diseases and conditions.
In conclusion, the global Nicotinamide Riboside (NR) market is poised for significant growth due to its diverse applications and increasing demand. However, it must navigate various challenges to sustain this growth. Technological innovation and strategic corporate activities will be crucial in overcoming these obstacles and unlocking the full potential of the NR market.
4 Global Nicotinamide Riboside (NR) Market Analysis by Type
In 2024, the global Nicotinamide Riboside (NR) market is projected to generate a total revenue of $201737 thousand USD. Specifically, the revenue distribution by type is as follows: NR with a purity of ≥98% is expected to contribute $80772 thousand USD, accounting for 40.04% of the total market revenue. NR with a purity of ≥99% is forecasted to generate $79920 thousand USD, representing 39.62% of the total revenue. The remaining segment, which includes NR with purity below 98%, is anticipated to produce $41046 thousand USD, making up 20.35% of the total market revenue.
Table Global Nicotinamide Riboside (NR) Market Size and Share by Type in 2024
Type | Market Size in 2024 (K USD) | Market Share in 2024 (%) |
|---|---|---|
Purity: ≥98% | 80772 | 40.04% |
Purity: ≥99% | 79920 | 39.62% |
Others | 41046 | 20.35% |
5 Global Nicotinamide Riboside (NR) Market Analysis by Application
In 2024, the global Nicotinamide Riboside (NR) market is projected to achieve a total revenue of $201,737 thousand USD, with the majority of this revenue driven by the Supplement application segment. Specifically, the Supplement application is expected to generate $142,663 thousand USD, accounting for 70.72% of the total market revenue. The Cosmetic application is forecasted to contribute $36,399 thousand USD, representing 18.04% of the total revenue. The remaining segment, classified as “Others,” is anticipated to produce $22,675 thousand USD, making up 11.24% of the total market revenue.
Table Global Nicotinamide Riboside (NR) Market Size and Share by Application in 2024
Application | Market Size in 2024 (K USD) | Market Share in 2024 (%) |
|---|---|---|
Supplement | 142663 | 70.72% |
Cosmetic | 36399 | 18.04% |
Others | 22675 | 11.24% |
6 Global Nicotinamide Riboside (NR) Market Analysis by Region
In 2024, the global Nicotinamide Riboside (NR) market is projected to achieve a total revenue of $201,737 thousand USD. Among the major regions, North America is expected to generate $69,924 thousand USD, representing 34.66% of the total market revenue. Europe will contribute $61,066 thousand USD, accounting for 30.28% of the total revenue. Asia-Pacific is forecasted to produce $61,113 thousand USD, making up 30.30% of the total market revenue. Latin America is anticipated to generate $3,964 thousand USD, contributing 1.96% of the total revenue, while the Middle East & Africa will produce $5,670 thousand USD, representing 2.81% of the total market revenue.
Figure Global Nicotinamide Riboside (NR) Market Share by Region in 2024
7 Top 3 Companies of Global Nicotinamide Riboside (NR) Market
7.1 Longerlive Tech
Company Introduction and Business Overview:
Longerlive Tech is a leading biotechnology company established in 2016, headquartered in Shenzhen, China. The company specializes in the development and production of high-tech biotechnology products, with a primary focus on Nicotinamide Riboside (NR) and its derivatives. Longerlive Tech has positioned itself as a key player in the NR market by leveraging advanced research and development capabilities, combined with a strong commitment to quality and innovation. The company’s manufacturing base is located in China, and its products are sold worldwide. Longerlive Tech’s monthly NR production capacity exceeds 1,000 kg, with a purity level of approximately 99%, meeting or exceeding international standards.
Products Offered:
Longerlive Tech’s main product is Nicotinamide Riboside Chloride (NR), a precursor to the essential coenzyme nicotinamide adenine dinucleotide (NAD+). This product is widely used in food nutritional ingredients and cosmetic raw materials. NR is known for its ability to enhance cellular metabolism and improve overall health and longevity. The company also offers derivatives such as Nicotinamide Mononucleotide (NMN), which further expands its product portfolio and market reach.
Sales Revenue in the Latest Year:
In the latest year, Longerlive Tech achieved a sales revenue of $12,995 thousand USD from its NR products. This significant revenue reflects the company’s strong market position and growing demand for its high-quality NR products. Longerlive Tech’s gross margin for NR sales was 47.34%, indicating its ability to maintain profitability while expanding its market share.
7.2 Chroma Dex
Company Introduction and Business Overview:
Chroma Dex is a globally recognized nutraceutical company founded in 1999, headquartered in California, USA. The company is dedicated to improving the way people age through scientific research and innovation. Chroma Dex collaborates with leading universities and research institutions worldwide to explore the potential of NAD+ and develop novel ingredients. Its flagship product, TRU NIAGEN®, is the world’s first and only FDA-safety reviewed form of Nicotinamide Riboside (NR). Chroma Dex’s commitment to scientific rigor and extensive intellectual property protection has solidified its position as a leader in the NR market.
Products Offered:
Chroma Dex offers TRU NIAGEN®, a patented form of Nicotinamide Riboside (NR) that has been clinically proven to increase NAD+ levels in humans. This product is marketed directly to consumers and is backed by multiple clinical trials demonstrating its safety and efficacy. TRU NIAGEN® is available in various forms, including capsules and powder, making it accessible to a wide range of consumers. The company also explores new applications for NR through ongoing research, further expanding its product offerings and market potential.
Sales Revenue in the Latest Year:
Chroma Dex reported a sales revenue of $6,164 thousand USD from its NR products. Despite facing challenges such as the COVID-19 pandemic, the company maintained a strong market presence with a gross margin of 56.23%. Chroma Dex’s continuous innovation and strategic partnerships, such as with Nestlé Health Science, have contributed to its sustained growth and market leadership.
7.3 Bontac Bio-Engineering
Company Introduction and Business Overview:
Bontac Bio-Engineering is a prominent biotechnology company established in 2012, headquartered in Shenzhen, China. The company specializes in biocatalysis technology and offers a range of coenzyme products, customized enzyme catalysis services, and high-value-added APIs and intermediates. Bontac Bio-Engineering’s focus on advanced biocatalysis technology has enabled it to produce high-purity NR, positioning it as a key player in the global NR market. The company’s products are primarily sold in Asia, with expanding sales regions globally.
Products Offered:
Bontac Bio-Engineering offers Nicotinamide Riboside (NR) with a purity level of ≥98%. This high-purity NR is used in various applications, including dietary supplements and cosmetic formulations. The company’s expertise in biocatalysis ensures the production of high-quality NR, meeting the stringent requirements of the global market. Bontac Bio-Engineering’s product portfolio also includes other coenzyme products and customized solutions, further diversifying its market reach.
Sales Revenue in the Latest Year:
Bontac Bio-Engineering achieved a sales revenue of $5,136 thousand USD from its NR products. The company’s gross margin was 55.59%, reflecting its efficiency in production and strong market competitiveness. Bontac Bio-Engineering’s continuous investment in research and development, combined with its focus on quality and innovation, has enabled it to maintain a significant market share in the NR industry.